Neuronetics attracts Christopher Thatcher as CEO
This article was originally published in Clinica
Executive Summary
Neuronetics, which specializes in transcranial magnetic stimulation (TMS) for depression, has made Christopher Thatcher president and CEO. Mr Thatcher was most recently divisional vice-president and business unit manager of the Reichert Technology Global Business Unit of Ametek, where he was responsible for revitalizing the brand and expanding the business globally. Prior to this, he was president of Integra Life Sciences’ neurosurgery division and corporate initiatives; vice-president cataract and vitreoretinal surgery at Bausch + Lomb; and held senior sales and marketing roles at Allergan. Neuronetics’ flagship NeuroStar TMS device received US FDA 510(k) clearance in 2008 for drug-resistant depression. Mr Thatcher replaces Bruce Shook, who in July left Neuronetics after 11 years to become president and CEO of Intact Vascular.